Oncotelic Therapeutics, Inc. (OTLC): Total Liabilities
$131.36M
As of 2025-12-31
$131.31M
As of 2026-06-30
+98.0%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $131.36M | +584.2% | 2026-04-15, Balance as of period end |
| 2024-12-31 | $19.20M | +4.3% | 2026-04-15, Balance as of period end |
| 2023-12-31 | $18.40M | +8.7% | 2025-04-15, Balance as of period end |
| 2022-12-31 | $16.92M | n/a | 2024-04-12, Balance as of period end |
| No annual figure between 2011-12-31 and 2022-12-31. | |||
| 2011-12-31 | $2.26M | -79.1% | 2012-03-28, Balance as of period end |
| 2010-12-31 | $10.82M | n/a | 2012-03-28, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Oncotelic Therapeutics, Inc. (OTLC) | 2025-12-31 | $131.36M | +584.2% |
| Erasca, Inc. (ERAS) | 2025-12-31 | $70.98M | -10.2% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $52.51M | -55.1% |
| Harrow, Inc. (HROW) | 2025-12-31 | $347.39M | +8.7% |
| MBX Biosciences, Inc. (MBX) | 2025-12-31 | $15.92M | +43.5% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $141.50M | +146.0% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $369.84M | +4.9% |
| Nkarta, Inc. (NKTX) | 2025-12-31 | $91.88M | -1.4% |
| Oric Pharmaceuticals, Inc. (ORIC) | 2025-12-31 | $24.53M | -20.9% |
Compare OTLC, ERAS, TNGX, HROW side by side · Screen every company in Pharmaceutical Preparations ↗